ReviewReumatologia2025
Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis: a comprehensive review.
Review in Reumatologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnosis and Treatment Pathway for Eosinophilic Granulomatosis with Polyangiitis in the Allergy Department.Diagnostics (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disorder characterized by eosinophil-rich inflammation and systemic necrotizing vasculitis affecting small to medium-sized vessels. The pathogenesis of EGPA is complex, involving both eosinophilic and vasculitic mechanisms, which contribute to a wide array of clinical manifestations. Treatment strategies primarily focus on immunosuppression, including glucocorticosteroids and biologic agents targeting eosinophils, to manage the diverse manifestations and improve patient outcomes. The authors reviewed the MEDLINE and PubMed databases to provide an updated overview of the pathogenetic mechanisms and current therapeutic strategies for the management of EGPA. We emphasize the diverse pathogenetic mechanisms underlying EGPA, focusing on both eosinophilic and vasculitic phenotypes. Additionally, we highlight contemporary therapeutic strategies, particularly the use of biologic agents targeting eosinophils, which represent a significant advancement in the management of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.